[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-cardia-body-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-cardia-body-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,73,117,157,193,216,261],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100575121","phase-3-quality-of-life-after-billroth-ii-or-roux-en-y-for-gastric-cancer-100575121",false,"NCT06768164","Quality of Life After Billroth II or Roux-en-Y for Gastric Cancer","Health-Related Quality Of Life After Partial Gastrectomy for Gastric Cancer: Comparison of Reconstruction by Billroth II or Roux-en-Y. A Randomized, Comparative, Multicentric, Single-blinded Study","BYQoL-GC","Inclusion Criteria:\n\n* Patients aged ≥ 18 years, men or women\n* Patients treated for adenocarcinoma of the antrum accessible to a surgical treatment with curative intent by distal gastrectomy. If patients present a linitis plastica, negative proximal and distal margin will be evaluated at the beginning of the surgery before randomization in order to perform a R0 resection\n* Patients with a registration in a national health care system (CMU included) (registered or being a beneficiary of such a scheme)\n* Patients able to understand and fulfill questionnaires in French language\n* Patients having given their written informed consent prior to participation in the study\n\nExclusion Criteria:\n\n* Patients with preoperative peritoneal metastasis or distant metastasis\n* Palliative surgery patients\n* Patients under tutorship or curatorship and protected adults\n* Patients on AME (Aide Médicale de l'Etat = State Medical Assistance)\n* Patients deprived of liberty by judicial or administrative decision and patients under psychiatric care (admitted to a health or social care establishment)\n* Patients unable to give their consent\n* Pregnant or breastfeeding women\n* Women of childbearing age without effective contraception","ALL","18 Years",{"count":20,"type":21},250,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The treatment of a local distal gastric cancer remains surgical before or after chemotherapy. Partial gastrectomy is recommended for distal location cancer The recommendations for restoring continuity are less evident. There are two main techniques: the Roux-En-Y (REY) requiring 2 anastomoses (gastro-jejunostomy and entero-enterostomy) and the Billroth 2 (B2) with a single anastomosis (gastro-jejunostomy). The choice remains matter of debate.\n\nThere was no difference on the global health status score from the QLQ-C30 questionnaire. However, the health-related quality of life (HRQoL) was significantly improved only in the REY group between pre- and post-gastrectomy. A significant difference for endoscopic gastritis in favor of the REY group was reported.\n\nThe purpose of this study is to determine which surgical technique improve the health related quality of life after distal gastrectomy.",[27],"Gastric (Cardia, Body) Cancer",[29,30],"gastric cancer","gastrectomy","RECRUITING","2026-05-18",{"date":34,"type":35},"2026-05-20","ACTUAL",{"date":37,"type":35},"2026-03-20",{"date":39,"type":21},"2031-04",{"name":41,"class":42},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100592962","phase-2-timing-of-minimally-invasive-local-treatment-after-first-line-systemic-therapy-in-oligometastatic-esophageal-or-gastric-adenocarcinoma-100592962","NCT07000253","Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma","Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma: A Randomized Prospective Clinical Study (OMEC-5)","OMEC-5","Inclusion Criteria:\n\n* Age ≥18 years\n* Ability to provide written informed consent\n* Histologically confirmed esophageal, gastric or gastroesophageal junction tumor with oligometastatic (M1) disease defined according to the OMEC consensus statement:\n\n  * One organ with ≤3 metastases or 1 involved extra-regional lymph node station (based on the TNM 8 classification)\n  * ≤3 unilobar liver metastases or ≤2 bilobar liver metastases\n  * ≤ 3 unilateral lung metastases\n  * Unilateral adrenal gland involvement\n  * Metastasis confined to 1 bone structure or 1 soft tissue compartment\n* Synchronous oligometastatic disease with a resectable primary tumor or metachronous oligometastatic disease (in the event of a locoregional recurrence this should be resectable)\n* Metastases should be deemed amenable by the international multidisciplinary expert team for radical local treatment\n* WHO performance status 0-2\n* Indication for checkpoint inhibition and\u002For targeted therapy\n\n  * PD-L1 with a CPS of 1 or higher as per local clinical practice for immunotherapy use\n  * HER2 overexpression as per local clinical practice for trastuzumab use\n  * Claudin 18.2 overexpression as per local clinical practice for zolbetuximab use.\n  * Any other biomarker that allows targeted therapy in first line approved by EMA\n* No prior systemic therapy for metastatic disease\n* CT-scan ≤8 weeks prior to inclusion\n* Ability to undergo local treatment and start systemic treatment beyond 18 weeks of total systemic treatment.\n\nExclusion Criteria:\n\n* Squamous cell carcinoma\n* Brain metastases\n* Peritoneal or pleural carcinomatosis\n* Patients with MSI dMMR\n* Uncontrolled immunodeficiency (e.g. AIDS)\n* Peripheral neuropathy \\>CTCAE grade 1, precluding start of full dose oxaliplatin treatment\n* Both organ metastasis and extra-regional lymph node metastasis\n* Conditions precluding local treatment or systemic therapy for oligometastatic disease:\n\n  * Serious medical comorbidities precluding local treatment (e.g., interstitial lung disease in patients with pulmonary metastasis)\n  * Clinical or radiological evidence of spinal cord compression or epidural tumor within 2 mm of the spinal cord\n  * Simultaneous other malignancy or previous other malignancy with a disease-free period of \\\u003C5 years, except adequately treated non-melanoma skin cancer or in-situ cancers\n  * Uncontrolled (bacterial) infections\n  * Significant concomitant diseases preventing the safe administration of study drugs or likely to interfere with study assessments\n  * Uncontrolled angina pectoris, cardiac failure or clinically significant arrhythmias\n  * Continuous use of immunosuppressive agents equivalent to \\>10 mg daily prednisone\n  * Concurrent use of the antiviral agent sorivudine or chemically related analogues, such as brivudine\n  * Pregnancy or breast feeding\n  * Patients (M\u002FF) with reproductive potential not implementing adequate contraceptive measures",{"count":53,"type":21},290,[55,24],"PHASE2","Purpose of the Study:\n\nThis clinical study investigates whether a shorter or longer duration of systemic therapy before local treatment (surgery or radiation) results in better disease control in patients with esophageal or gastric cancer with a limited number of metastases, also known as oligometastases.\n\nBackground:\n\nIn about 25% of patients with advanced esophageal or gastric cancer, the disease spreads to only a few sites (oligometastatic disease). Prior studies suggest that local treatment after systemic therapy may extend survival in this subgroup. However, it is unclear how long systemic therapy should last before initiating local treatment. The OMEC-5 study aims to clarify this and identify potential biomarkers for treatment response.\n\nStudy Design:\n\nInitiated by Amsterdam UMC and UMCU and conducted in multiple hospitals across Europe.\n\nTotal of 414 patients to be enrolled.\n\nDuration: \\~53 months (35 months enrollment + 18 months follow-up).\n\nApproved by the medical ethics committee at Amsterdam UMC.\n\nProcedure:\n\nEligibility screening: Includes physical exam, blood tests (incl. circulating tumor cells), medical history review, and confirmation of oligometastases by an expert panel.\n\nInitial treatment: All participants receive 4 months of standard systemic therapy (chemotherapy + immunotherapy and\u002For targeted therapy depending on tumor markers like HER2 or Claudin 18.2).\n\nResponse assessment (Review 1): Imaging and\u002For laparoscopic examination.\n\nIf oligometastases persist and tumors have not progressed, participants are randomized into two groups:\n\nGroup A (longer systemic therapy): 4 more months of systemic therapy, then local treatment if disease is stable, followed by 4 months of immunotherapy ± targeted therapy.\n\nGroup B (shorter systemic therapy): Immediate local treatment followed by 4 months of systemic therapy, then reassessment and potentially 4 months of immunotherapy ± targeted therapy.\n\nFollow-up: Regular scans and quality-of-life questionnaires (5 times), and periodic blood sampling (4 times).\n\nTreatments Involved:\n\nChemotherapy: CapOx or FOLFOX\n\nImmunotherapy: nivolumab or pembrolizumab\n\nTargeted therapy: trastuzumab (HER2-positive) or zolbetuximab (Claudin 18.2-positive)\n\nPotential Benefits and Risks:\n\nPatients may benefit from better disease control and a personalized treatment strategy.\n\nKnown side effects relate to the standard treatments used (chemo, immuno, targeted therapies), and no extra medical risk is expected beyond routine care.\n\nPossible inconveniences include blood draws, scans, minor surgery (laparoscopy), and time investment.\n\nData and Sample Handling:\n\nPersonal data and tumor\u002Fblood samples are coded and securely stored.\n\nData may be used for future cancer research if the patient consents.\n\nParticipants can withdraw at any time.\n\nConfidentiality and Privacy:\n\nPatient data are kept confidential, and participants have rights to access or delete their data. Privacy measures comply with GDPR and Dutch law.\n\nCompensation and Insurance:\n\nParticipation is voluntary, with no financial compensation. Standard treatment costs are covered by healthcare insurance. No extra insurance is required, as the treatment aligns with standard care practices.",[58,59,60,61,62,27],"Esophageal Cancer","Gastric (Stomach) Cancer","Gastric Adenocarcinoma","Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","Esophageal Carcinoma","2026-05-03",{"date":65,"type":35},"2026-05-07",{"date":67,"type":35},"2026-04-29",{"date":69,"type":21},"2034-01",{"name":71,"class":42},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":98,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":43},"100572340","optimal-perioperative-pain-control-in-minimally-invasive-abdominal-cancer-surgery-100572340","NCT06731998","Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery","Evaluating Optimal Perioperative Pain Management: A Prospective Randomized Control Trial of Laparoscopic Transversus Abdominis Plane Block With Local Anesthetic, Laparoscopic Transversus Abdominis Plane Block Alone, and Local Anesthetic Alone in Minimally Invasive Oncologic Surgery","LapTAP","Inclusion Criteria:\n\n1. Male and female patients age ≥ 18 - 89\n2. Patients scheduled for elective (clinically indicated) hepatic, gastric, biliary, pancreatic, gynecologic, colorectal, other GI Minimally invasive oncologic surgery.\n3. Patients who have provided informed consent to participate in the study.\n4. Patients with an American Society of Anesthesiologists (ASA) physical status classification of I, II, or III.\n5. Patients undergoing procedures anticipated to last more than 1 hour but less than 8 hours.\n6. Patients able to understand and self-report pain using the designated pain Visual Analog Scale\n\nExclusion Criteria:\n\n1. Patients age less than 18 or ≥ 90\n2. Pre-existing hepatic dysfunction, cirrhosis\n3. Patients with an ASA classification of IV or higher.\n4. Patients with chronic pain disorders or on long-term opioid or analgesic therapy.\n5. Patients with known contraindications to the study drugs or procedures (e.g., allergy to LA or contraindications to LapTAP).\n6. Patients with cognitive impairments or psychiatric conditions that could interfere with pain assessment or understanding of informed consent.\n7. Patients unable to understand the language in which consent and study-related information are provided (The study and the study-related information will be in the English Language)..\n8. Patients who have undergone major surgery within the last 6 months.\n9. Female patients who are pregnant.\n10. Patients currently enrolled in another clinical trial that might interfere with the outcome measures of this study.","89 Years",{"count":83,"type":21},48,[85],"NA","This is a research study to evaluate the effectiveness of 3 different types of routine pain management regimens used during clinically indicated, minimally invasive oncologic (cancer) surgery. This project is considered \"Research\" and participation is voluntary. Upon enrollment in this study, the research team will collect data from the patient's medical records. The patient will undergo all of the normal testing and procedures required pre-operatively (standard of care). The study team will then randomly assign the patient (like a flip of a coin) to one of three different study arms for pain management during surgery:\n\n1. Laparoscopic Transversus Abdominis Plane Block (LapTAP) with Local Anesthetic (LA)\n2. Laparoscopic Transversus Abdominis Plane Block (LapTAP) only\n3. Local Anesthetic (LA) only The patient will receive standard pre- and post-operative care according to clinical guidelines (routine care). The study team will collect information from the patient's medical record for the first 24 hours after their surgery and upon discharge. This information will include pain scores, amount of medication required, any side effects the patient may have experienced, and satisfaction with pain control. Participation in the study will end upon discharge from the hospital.",[88,89,90,91,27,92,93,94,95,96,97],"Oncologic Surgery","Cancer","Cancer Surgery","Hepatic Cancer","Biliary Tract Cancer","Pancreatic Cancer Resectable","Gynecologic Cancers","Gastrointestinal Cancers","Colorectal Cancer","Minimally Invasive Surgical Procedures",[99,100,101,102,103,104,105,106,107],"Laparoscopic Transversus Abdominis Plane Block","Local Anesthetic","Laparoscopic Surgical Procedure","pain management","cancer","cancer surgery","oncologic surgery","perioperative pain management","minimally invasive surgical procedures","2025-09-15",{"date":110,"type":35},"2025-09-18",{"date":112,"type":35},"2025-02-05",{"date":114,"type":21},"2026-12",{"name":116,"class":42},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":127,"studyType":128,"phases":4,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":43},"100601756","impact-of-ces1-genotype-on-capecitabine-exposure-in-cancer-patients-100601756","NCT07114627","Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients","Exploratory Study of Capecitabine Pharmacokinetics and Hand-foot Syndrome in CES1 Variant Carriers: the ESCAPE Study","ESCAPE","In order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n* 18 years of age or older;\n* Planned to start treatment with concomitant capecitabine and oxaliplatin according to standard of care (irrespective of dose);\n* Fit for treatment with capecitabine and oxaliplatin as judged by the treating physician;\n* Capable of understanding and complying with protocol requirements and able to understand and sign the informed consent form.\n\nExclusion Criteria:\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Carrier of a known clinically relevant DPYD variant (i.e. \\*2A, \\*7, \\*13, c.1236G\\>A or c.2846A\\>T);\n* Any medical condition that is known to influence capecitabine absorption (i.e. a Roux-en-Y gastric bypass operation or complete gastric resection; an esophagectomy is not considered to impair absorption);\n* Prior treatment with fluoropyrimidines;\n* Use of DPD-inhibitors and\u002For allopurinol;\n* Known pregnancy at baseline.",{"count":126,"type":21},66,"2 Years","OBSERVATIONAL","In this study, the drug capecitabine is investigated. Capecitabine is commonly used to treat breast, colon, and stomach cancers. Capecitabine is taken in tablet form. In the body, capecitabine is converted into the active molecule that has anti-cancer effects. This molecule is called 5-FU. The transformation of capecitabine to 5-FU occurs through specific proteins in the liver, also known as enzymes.\n\nUnfortunately, capecitabine can also cause side effects. One of the most common side effects is hand-foot syndrome. In hand-foot syndrome, the palms of the hands and soles of the feet become red and painful. Previous research has shown that patients in whom one of the enzymes responsible for converting capecitabine in the liver does not function properly experience an increase in side effects frequency, particularly severe hand-foot syndrome. This specific enzyme is called CES1. It is believed that side effects occur more frequently because capecitabine is transformed more slowly, eventually leading to a prolonged exposure to 5-FU in the body.\n\nIn roughly one in three people, this enzyme functions less efficiently. To gain a better understanding of how this mechanism works, we aim to conduct this study. In this study, we will examine if patients with a less effective CES1 enzyme have higher amounts of 5-FU in their blood. We will also look into whether these patients develop side effects, such as hand-foot syndrome, more frequently. This information could eventually help us develop new strategies to reduce side effects for these patients in the future.",[131,27,58,132],"Solid Cancer","Colorectal Cancer (CRC)",[134,135,136,137,138,139,140,141,142,143,144,145,146,147,89],"CAPOX","CES1","carboxylesterase 1","Capecitabine","Pharmacokinetics","Pharmacogenetics","Oncology","SNP","Single-nucleotide polymorphism","rs2244613","Hand-foot syndrome","HFS","5-FU","ErasmusMC","2025-08-04",{"date":150,"type":35},"2025-08-11",{"date":152,"type":35},"2025-02-18",{"date":154,"type":21},"2027-06",{"name":156,"class":42},"Erasmus Medical Center",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":183,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":43},"100594332","phase-2-neoadjuvant-nab-paclitaxel-plus-oxaliplatin-s-1-and-sintilimab-in-early-onset-resectable-gastric-cancer-100594332","NCT07018063","Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer","Efficacy and Safety of Neoadjuvant Nab-Paclitaxel Combined With Oxaliplatin, S-1, and Sintilimab in Patients With Locally Advanced Resectable Early-onset Gastric Cancer: A Phase II, Single-Arm, Open-Label Clinical Trial","YOUNG-NEOS","Inclusion Criteria:\n\n* Participants must meet all of the following inclusion criteria:\n* Male or female, aged ≥16 and ≤45 years;\n* Karnofsky performance score ≥70% or ECOG performance status 0-1;\n* Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEJ).\n* For gastric body cancer: clinical stage cT3-T4a N+ M0;\n* For GEJ cancer: clinical stage cT2-T4a N+ M0;\n* For cT4b Nany M0 cases: location may be gastric body or GEJ.\n* Staging is based on contrast-enhanced CT, MRI (if needed), and endoscopic ultrasonography (EUS) (if needed);\n* Assessed as resectable after multidisciplinary team (MDT) discussion;\n* Surgical evaluation confirms that D2 radical gastrectomy is feasible;\n* Sufficient physical condition and organ function to tolerate major abdominal surgery;\n* Baseline laboratory tests meet the following criteria:\n* Hemoglobin ≥90 g\u002FL\n* Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL\n* Platelets ≥100×10⁹\u002FL\n* ALT and AST ≤2.5× upper limit of normal (ULN)\n* Alkaline phosphatase (ALP) ≤2.5× ULN\n* Total bilirubin \\\u003C1.5× ULN\n* Serum creatinine \\\u003C1× ULN\n* Serum albumin ≥30 g\u002FL\n* No severe comorbidities that may limit life expectancy to \\\u003C3 years;\n* Participant is willing and able to comply with the study protocol during the study period;\n* Written informed consent must be signed before screening. Participants must understand their right to withdraw at any time without any loss of benefits;\n* Willing to provide blood and tissue samples.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n* Patients with HER-2 positive gastric cancer, as determined by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH);\n* Patients with dMMR (deficient mismatch repair) or MSI-H (microsatellite instability-high) tumors, as determined by IHC;\n* Pregnant or breastfeeding women;\n* Prior treatment for gastric cancer with cytotoxic chemotherapy, radiotherapy, or immunotherapy;\n* History of other malignancies within the past 5 years;\n* Active autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis;\n* Active inflammatory bowel diseases, such as Crohn's disease or ulcerative colitis;\n* Currently receiving systemic corticosteroids or other immunosuppressive therapy;\n* Prior organ transplantation or use of anti-rejection medications;\n* Active tuberculosis, HIV infection, or severe active hepatitis B or C;\n* History of uncontrolled epilepsy, central nervous system disorders, or psychiatric illnesses that, in the investigator's judgment, may interfere with informed consent or compliance with oral medication;\n* Clinically significant (active) cardiac diseases, including symptomatic coronary artery disease, NYHA class II or above congestive heart failure , severe arrhythmias requiring medical intervention, or myocardial infarction within the past 12 months;\n* Presence of upper gastrointestinal obstruction that may impair the oral intake or absorption of S-1;\n* Severe uncontrolled recurrent infections or other uncontrolled serious comorbidities;\n* Use of any investigational drugs within 4 weeks prior to study enrollment.","16 Years","45 Years",{"count":168,"type":21},35,[55],"This study aims to evaluate the effectiveness and safety of a preoperative treatment (called neoadjuvant therapy) combining four drugs-nab-paclitaxel, oxaliplatin, S-1, and sintilimab-for patients with locally advanced, resectable early-onset gastric cancer (diagnosed at age 45 or younger).\n\nAll participants will receive this drug combination before undergoing surgery to remove the tumor. The goal is to shrink the tumor, increase the chance of complete surgical removal, and improve long-term outcomes.\n\nThis is a single-arm, open-label, phase II clinical trial, meaning all participants will receive the same treatment, and both doctors and patients will know what drugs are being used. The study is being conducted at Peking University People's Hospital.",[27,172,173],"Stomach Adenocarcinoma","Locally Advanced",[29,175,176,177,178,179,180,181,182],"Neoadjuvant therapy","Early-onset gastric cancer","Immunotherapy","Chemotherapy","Single-arm trial","Phase II trial","Perioperative treatment","China","NOT_YET_RECRUITING","2025-06-04",{"date":186,"type":35},"2025-06-12",{"date":188,"type":21},"2025-10-01",{"date":190,"type":21},"2030-06-01",{"name":192,"class":42},"zhoujing",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":183,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100585587","phase-2-ivonescimab-ak112-plus-paclitaxel-as-second-line-therapy-in-patients-with-advanced-ggej-cancer-100585587","NCT06904300","Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G\u002FGEJ Cancer","A Randomized, Controlled, Multi-center Phase II Study of Ivonescimab (AK112) Plus Paclitaxel Versus Paclitaxel With or Without Ramucirumab as Second-line Therapy in Subjects With Advanced Gastric or Gastroesophageal Junction（G.GEJ）Cancer Who Failed Immunochemotherapy","Inclusion Criteria:\n\n1. Voluntary written informed consent provided\n2. Age ≥18 and ≤75 years, regardless of gender\n3. Histologically or cytologically confirmed advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma\n4. Prior treatment failure with PD-1\u002FL1 inhibitor combined with platinum-based chemotherapy; no other systemic antitumor therapy allowed (only first-line therapy permitted, with initial immunotherapy duration ≥12 weeks).Note: Patients who previously received adjuvant\u002Fneoadjuvant PD-1 inhibitor plus platinum-based chemotherapy for non-metastatic disease or curative-intent platinum chemoradiotherapy + PD-1 inhibitor for locally advanced or recurrent\u002Fmetastatic disease are eligible if disease progression occurred within \\\u003C6 months after the last treatment and no subsequent systemic therapy was administered.\n5. ECOG performance status of 0-1\n6. Life expectancy ≥3 months\n7. At least one measurable lesion per RECIST v1.1. Previously irradiated lesions may qualify as target lesions if evidence of post-radiotherapy progression exists and no alternative target lesions are available.\n8. Adequate organ function:\n\n   Hematology (without transfusions\u002Fgrowth factors for 7 days): ANC ≥1.5×10⁹\u002FL; platelets ≥100×10⁹\u002FL; hemoglobin ≥90 g\u002FL.\n\n   Liver: Total bilirubin ≤1.5×ULN; AST\u002FALT ≤2.5×ULN (≤5×ULN for hepatic metastases); albumin ≥28 g\u002FL.\n\n   Kidney: Serum creatinine ≤1.5×ULN and CrCl ≥50 mL\u002Fmin; urine protein \\\u003C2+ or 24-hour urinary protein \\\u003C1.0 g.\n\n   Coagulation: INR\u002FPT ≤1.5×ULN (unless on anticoagulants with therapeutic ranges maintained).\n\n   Cardiac: LVEF ≥50%.\n9. For females of childbearing potential: Negative pregnancy test within 3 days prior to treatment; highly effective contraception required during screening and for 120 days post-treatment. Postmenopausal women (amenorrhea ≥1 year) or surgically sterilized females are exempt.\n10. For non-sterilized males with childbearing partners: Effective contraception during screening and for 120 days post-treatment.\n11. Willingness and ability to comply with protocol-specified visits, treatments, and laboratory tests.\n\nExclusion Criteria:\n\n1. Histologically or cytologically confirmed as other pathological types (e.g., squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma). Mixed pathological types will be categorized based on the predominant component; only subjects with \\>70% adenocarcinoma component confirmed by a pathologist may enroll.\n2. History of other malignancies within 3 years prior to enrollment. Exceptions include malignancies cured by local therapy (e.g., basal or squamous cell skin cancer, superficial bladder cancer, in situ cervical or breast cancer).\n3. Systemic anti-cancer therapy (e.g., chemotherapy, radiotherapy, immunotherapy, targeted therapy \\[\\\u003C2 weeks for small-molecule agents\\], biologics) within 3 weeks prior to first dose; palliative local therapy for non-target lesions within 2 weeks.\n4. Prior immunotherapy other than PD-1\u002FPD-L1 inhibitors, including checkpoint inhibitors (anti-CTLA-4, anti-CD47, anti-SIRPα, anti-LAG-3), checkpoint agonists (ICOS, CD40, CD137, GITR, OX40), cell therapies, or biologics targeting tumor immunity.\n5. Prior treatment with ramucirumab, VEGFR2 antagonists, or other VEGFR2-targeting antibodies\u002Fproteins.\n6. Prior use of taxane-based agents (e.g., paclitaxel, docetaxel) in first-line systemic therapy.\n7. Prior PD-1\u002FPD-L1 inhibitor treatment with any of the following:\n\n   1. Grade ≥3 irAEs (excluding endocrine irAEs), irAEs leading to permanent discontinuation, Grade 2 immune-related cardiotoxicity, or any-grade neurological\u002Focular irAEs.\n   2. Unresolved toxicities from prior PD-1\u002FPD-L1 therapy (not resolved to ≤Grade 1). Grade ≥2 endocrine toxicities are allowed if stable and asymptomatic under replacement therapy.\n   3. IrAEs requiring non-corticosteroid immunosuppressants or recurrent irAEs necessitating systemic corticosteroids.\n8. Hypersensitivity to any study drug component or history of severe allergic reactions to monoclonal antibodies.\n9. Bleeding diathesis or coagulation disorders.\n10. Imaging showing tumor invasion of adjacent organs\u002Fvessels, necrosis, or cavitation posing risk of perforation\u002Fhemorrhage.\n11. Major surgery\u002Ftrauma within 30 days prior to first dose or planned surgery within 30 days post-dose; minor surgery within 3 days prior to first dose (excluding PICC\u002Fport placement).\n12. Gastrointestinal risks:Esophagogastric varices, severe ulcers, unhealed wounds, perforation, fistula, abscess, or acute bleeding within 6 months; Arterial thromboembolism or Grade ≥3 venous thromboembolism (per NCI CTCAE v5.0), TIA, stroke, hypertensive crisis, or COPD exacerbation within 6 months; Uncontrolled hypertension (≥160\u002F100 mmHg on oral therapy).\n13. Cardiac history:Myocarditis, cardiomyopathy, malignant arrhythmia; Unstable angina, MI, NYHA Class ≥2 heart failure, or aortic aneurysm within 12 months; Poorly controlled arrhythmias or ischemia.\n14. Active autoimmune disease requiring systemic treatment within 2 years (excluding hormone replacement).\n15. Symptomatic effusions requiring diuretics or drainage (pleural, pericardial, or ascites).\n16. Severe infection (hospitalization-required\u002Fsepsis) within 4 weeks; active infection requiring systemic antibiotics within 2 weeks (excluding antiviral therapy for HBV\u002FHCV).\n17. Active tuberculosis (must be ruled out if suspected) or active syphilis.\n18. Organ or stem cell transplant history (excluding corneal transplants).\n19. Immunodeficiency:HIV-positive; Chronic systemic corticosteroids\u002Fimmunosuppressants.\n20. Chronic viral hepatitis:Active HBV (HBsAg-positive with HBV DNA \\>500 IU\u002FmL or \\>2500 copies\u002FmL); Active HCV (allowed if cured or HCV RNA-negative).\n21. Live\u002Fattenuated vaccines administered within 30 days prior to first dose or planned during the study (inactivated vaccines permitted).\n22. Pregnancy, lactation.\n23. History of psychiatric disorders, substance abuse, or alcoholism.\n24. Other conditions deemed ineligible by the investigator.","75 Years",{"count":202,"type":21},110,[55],"A Randomized, Controlled, Multi-center Phase II Study of Ivonescimab (AK112) plus Paclitaxel versus Paclitaxel with or without Ramucirumab as second-line therapy in subjects with advanced gastric or gastroesophageal junction（G\u002FGEJ）cancer who failed immunochemotherapy",[27],[207],"immunotherapy",{"date":209,"type":35},"2025-06-05",{"date":211,"type":21},"2025-08-15",{"date":213,"type":21},"2028-12-31",{"name":215,"class":42},"Sun Yat-sen University",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":243,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":72},"100518299","phase-2-total-neoadjuvant-flot-chemotherapy-in-locally-advanced-gastric-and-gastroesophageal-junction-cancer-100518299","NCT06028737","Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer","Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin, and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Multi-center, Open-label Trial, Phase 2\u002F3","OCTASUR","Inclusion Criteria:\n\n* Tumor spread according to TNM: ≥cT3 and\u002For ≥cN0 and M0 (except of invasion of the common hepatic artery, celiac trunk, proximal part of the splenic artery, aorta, head of the pancreas);\n* Performance status by Eastern Cooperative Oncology Group (ECOG): 0 - 1;\n* Histologically confirmed gastric adenocarcinoma or gastroesophageal junction (Siewert type 2\u002F3) adenocarcinoma.\n* Differentiation grade: G0 - G4;\n* Tumor localization: cardio-esophageal junction (Siewert 2, 3), cardiac part of the stomach, body of the stomach, antral part of the stomach, pyloric part of the stomach;\n* Tumor extension: esophagus, diaphragm, liver, body and tail of the pancreas, anterior abdominal wall, small and large intestine, distal part of the splenic artery, spleen;\n* Patient agrees to participate in this biomedical study.\n\nExclusion Criteria:\n\n* Presence of another oncological disease at a different site if less than 5 years have passed since radical treatment.\n* Comorbidities or patient conditions that preclude the administration of chemotherapy.","80 Years",{"count":226,"type":21},150,[55,24],"The main goal of this study is to investigate the proportion of participants with locally advanced gastric and gastroesophageal adenocarcinoma without previous treatment during the last 5 years who can tolerate all planned cycles of chemotherapy and radical surgical treatment who will be prospectively randomized into two groups to undergo one of two chemotherapy regimens, followed by surgery:\n\n1. 8 cycles of Total Neoadjuvant ChemoTherapy (TNT) with 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, and Docetaxel (FLOT) followed by surgery.\n2. 4 cycles of Neoadjuvant FLOT chemotherapy scheme preoperatively and 4 adjuvant FLOT cycles postoperatively.",[230,231,232,60,233,234,235,236,237,238,239,178,240,241,242,27],"Gastric Cancer","Stomach Cancer","GastroEsophageal Cancer","Gastroesophageal Junction Adenocarcinoma","Advanced Gastric Adenocarcinoma","Gastric Neoplasm","Stomach Neoplasm","Gastrointestinal Cancer","Advanced Gastroesophageal Junction Adenocarcinoma","Advanced Gastric Carcinoma","Gastrectomy","Gastrectomy for Gastric Cancer","Gastric Resection",[244,245,246,240,247,248,249,250,251],"Total neoadjuvant chemotherapy","FLOT","Fluoruracil","Perioperative chemotherapy","Docetaxel","Leucovorin","Gastric resection","Gastric cancer","2025-04-30",{"date":254,"type":35},"2025-05-06",{"date":256,"type":35},"2025-03-25",{"date":258,"type":21},"2032-12-31",{"name":260,"class":42},"Ukrainian Society of Clinical Oncology",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":268,"targetDuration":270,"studyType":128,"phases":4,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":43},"100570087","the-correlation-between-blood-concentration-of-sintilimab-and-efficacy-and-adverse-reactions-in-patients-with-advanced-gastric-cancer-100570087","NCT06702683","The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer","Study on the Correlation Between Blood Concentration of Sintilimab and Related Predictors with Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer","Inclusion Criteria:\n\nA. Patients who were diagnosed with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; B. Patients who plan to be treated with Sintilimab; C.ECOG score of 0-2; D. Expected survival ≥3 months; E. The patient who have good compliance, follow-up, and can cooperate with relevant treatment and examination; F. Agree to participate in the study and sign the informed consent\n\nExclusion Criteria:\n\nA. Patients who clinical information and data are incomplete; B. Patients who treated with immune checkpoint inhibitors within 6 months",{"count":269,"type":21},112,"3 Years","Compared with other anti-tumor drugs, immune checkpoint inhibitors (ICIs) have their own unique pharmacokinetics (PK) and pharmacodynamics (PD), and affect patient clinical outcomes. However, at present, the data on the PK and PD characteristics of ICIs in the Chinese population are still lacking, thus further clinical trials are needed to verify them. At the same time, a large proportion of patients have no response to ICIs or the efficacy is poor, and even bring greater side effects, so it is particularly important to find effective biomarkers to predict the efficacy and adverse reactions of patients with ICIs treatment.The purpose of this study is to explore the correlation between blood concentration of Sintilimab and related predictors with efficacy and adverse reactions in patients with advanced gastric cancer so as to provide clinical reference for individualized treatment of patients with gastric cancer.",[273,235,274,275],"Gastric Carcinoma","Gastric (cardia, Body) Cancer","Gastric Cancer Adenocarcinoma Metastatic","2024-11-21",{"date":278,"type":35},"2024-11-25",{"date":280,"type":35},"2023-02-17",{"date":282,"type":21},"2025-12-31",{"name":284,"class":42},"Lin Liu"]